NASDAQ:CRSP

Crispr Therapeutics Stock Earnings Reports

etoro logo Buy CRSP
*Your capital is at risk
$51.84
-5.11 (-8.97%)
At Close: Jun 05, 2026

CRISPR Therapeutics Earnings Calls

Mar 31, 2026
-$1.28 (-8.18%)
Release date May 04, 2026
EPS estimate -$1.18
EPS actual -$1.28
EPS Surprise -8.18%
Revenue estimate 6.064M
Revenue actual 1.458M
Revenue Surprise -75.96%
Dec 31, 2025
-$1.37 (-19.13%)
Release date Feb 12, 2026
EPS estimate -$1.15
EPS actual -$1.37
EPS Surprise -19.13%
Revenue estimate 4.719M
Revenue actual 864K
Revenue Surprise -81.69%
Sep 30, 2025
-$1.17 (7.14%)
Release date Nov 10, 2025
EPS estimate -$1.26
EPS actual -$1.17
EPS Surprise 7.14%
Revenue estimate 9.122M
Revenue actual 889K
Revenue Surprise -90.25%
Jun 30, 2025
-$1.29 (12.24%)
Release date Aug 04, 2025
EPS estimate -$1.47
EPS actual -$1.29
EPS Surprise 12.24%
Revenue estimate 9.437M
Revenue actual 892K
Revenue Surprise -90.55%

Last 4 Quarters for CRISPR Therapeutics

Below you can see how CRSP performed 4 days prior and 4 days after releasing the earnings report. Also, you can see the pre-estimates and the actual earnings. This information can give you a slight idea of what you might expect for the next quarter's release.

Jun 30, 2025 Beat
Release date Aug 04, 2025
Price on release $59.59
EPS estimate -$1.47
EPS actual -$1.29
EPS surprise 12.24%
Date Price
Jul 29, 2025 $59.02
Jul 30, 2025 $57.68
Jul 31, 2025 $56.26
Aug 01, 2025 $56.09
Aug 04, 2025 $59.59
Aug 05, 2025 $55.59
Aug 06, 2025 $56.34
Aug 07, 2025 $55.96
Aug 08, 2025 $55.00
4 days before 0.97%
4 days after -7.70%
On release day -6.71%
Change in period -6.81%
Sep 30, 2025 Beat
Release date Nov 10, 2025
Price on release $54.58
EPS estimate -$1.26
EPS actual -$1.17
EPS surprise 7.14%
Date Price
Nov 04, 2025 $56.41
Nov 05, 2025 $56.99
Nov 06, 2025 $56.61
Nov 07, 2025 $55.12
Nov 10, 2025 $54.58
Nov 11, 2025 $55.21
Nov 12, 2025 $52.19
Nov 13, 2025 $51.11
Nov 14, 2025 $52.53
4 days before -3.24%
4 days after -3.76%
On release day 1.15%
Change in period -6.88%
Dec 31, 2025 Missed
Release date Feb 12, 2026
Price on release $48.93
EPS estimate -$1.15
EPS actual -$1.37
EPS surprise -19.13%
Date Price
Feb 06, 2026 $48.74
Feb 09, 2026 $49.70
Feb 10, 2026 $48.83
Feb 11, 2026 $48.32
Feb 12, 2026 $48.93
Feb 13, 2026 $53.07
Feb 17, 2026 $53.17
Feb 18, 2026 $53.52
Feb 19, 2026 $54.64
4 days before 0.390%
4 days after 11.67%
On release day 8.46%
Change in period 12.11%
Mar 31, 2026 Missed
Release date May 04, 2026
Price on release $53.58
EPS estimate -$1.18
EPS actual -$1.28
EPS surprise -8.18%
Date Price
Apr 28, 2026 $52.06
Apr 29, 2026 $50.71
Apr 30, 2026 $52.34
May 01, 2026 $51.63
May 04, 2026 $53.58
May 05, 2026 $52.38
May 06, 2026 $55.08
May 07, 2026 $52.42
May 08, 2026 $54.83
4 days before 2.92%
4 days after 2.33%
On release day -2.24%
Change in period 5.32%

CRISPR Therapeutics Earnings History

Earnings Calendar

FAQ

When is the earnings report for CRSP?
CRISPR Therapeutics (CRSP) has scheduled its earnings report for Aug 03, 2026 after the markets close.

What is the CRSP price-to-earnings (P/E) ratio?
CRSP P/E ratio as of Jun 05, 2026 (TTM) is -8.76.

What is the CRSP EPS forecast?
The forecasted EPS (Earnings Per Share) for CRISPR Therapeutics (CRSP) for the first fiscal quarter 2026 is -$1.20.

What are CRISPR Therapeutics's retained earnings?
On its balance sheet, CRISPR Therapeutics reported retained earnings of $1.46 million for the latest quarter ending Mar 31, 2026.

What Is an Earnings Report?
An earnings report is usually issued quarterly (Q1, Q2, Q3 & Q4) by public companies to report their performance. Earnings reports typically include net income, earnings per share, earnings from continuing operations, and net sales. Looking at the earnings report investors can start gauge the financial health of the company and make even better decisions whether to buy, sell, or stay in the company. Fundamental analysts and value investors will typically hunt for stocks that continue to show good financial ratios and use a decline as an exit point. One of the most anticipated numbers for analysis is earnings per share because it indicates how much the company earned for its shareholders. The report will also indicate a possible dividend.

Earnings Report Content
Earnings reports generally provide an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. These figures are typically measured against previous quarters/years. Furthermore, the earnings report usually includes a summary and analysis from the CEO or company spokesman, alongside a more general view of the financials and future forecast.

What To Know About Earnings Reports?
Announcement of earnings for a stock, particularly for well followed large-capitalization stocks, can move the market. Stock prices can fluctuate wildly on days when the quarterly earnings report is released. Despite good reports, stocks may very well fall if the investors were expecting more or they believe the next quarter will not be as good. Investors always try to be ahead of the market and future earnings/losses are often discounted into the current price of the stock. It is natural for stocks to start to move in either direction a few days before the release of an earnings report.
Click to get the best stock tips daily for free!
ABOUT CRISPR THERAPEUTICS AG
CRISPR Therapeutics
CRISPR Therapeutics AG, a gene editing company, focuses on developing gene-based medicines for serious diseases using its proprietary Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9) platform. Its CRISPR/Cas9 is a gene editing technology that allows for precise directed changes to genomic DNA. The company has a portfolio of therapeutic programs across a range of disease areas, including hemoglo...
GOLDEN STAR
Ticker Change Signal Date
RUN
$12.83
4.09% May 06
GLBE
$31.61
1.65% May 05
SAP
$172.39
7.18% May 05
FIZZ
$34.11
7.04% May 01
ADBE
$243.57
3.23% Apr 29

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE